GLPwatch
Papers (9189)
Page 133 of 154, ranked by citation count.
- Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.
- Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation.
- Calculating cost per event avoided using a composite number needed to treat.
- Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.
- Tirzepatide-New Evidence for the Treatment of Obesity From China.
- A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.
- Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.
- Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern.
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
- Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- Cardiovascular Outcomes Trials of Incretin-Based Therapies.
- Person-centered choice of anti-obesity pharmacotherapy.
- Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
- Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.
- Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.
- Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.
- Mazdutide: First Approval.
- Orforglipron in type 2 diabetes mellitus and obesity: an overview.
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
- Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.
- Gliptins, exenatide, liraglutide: "intestinal obstruction".
- Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.
- Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
- The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.
- Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
- Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.
- Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.
- Lessons From LEADER - All-round Leadership.
- Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.
- Tirzepatide Outperforms Dulaglutide for Type 2 Diabetes Control.
- Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
- [Lixisenatide (Lyxumia), subcutaneous].
- Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.
- Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
- Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.
- Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
- Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes.
- Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
- Interaction Between Glucagon-like Peptide 1 and Its Analogs with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity.
- [Treatment of an obese diabetic].
- Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
- Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
- Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.
- Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.
- Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity.
- Dulaglutide slows kidney disease in type 2 diabetes.
- The Potential Weight Loss Benefits Of Tirzepatide: A Double-Edged Sword?
- Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.
- Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.
- Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.
- Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT.
- Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot.
- Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167.
- Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".